MedWatch

New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"

Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.

Jacob Tolstrup, executive vice president and chief commercial officer of commercial operations at Lundbeck | Photo: PR / Lundbeck

The pipeline has failed, sales of migraine drug Vypeti, which cost billions to acquire, have failed, and so, it seems, has the firm’s ability to make money. Still, the pharmaceutical company’s new CCO, Jacob Tolstrup, is optimistic on Lundbeck’s behalf.

”2022 will be a growth year for Lundbeck in all regions,” says Tolstrup, executive vice president and chief commercial officer of commercial operations at Lundbeck.

Wouldn’t this follow a 2021 that has been pretty bad?

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs